Stool Collection Sub-Study of Exact Sciences Protocol 2018-01
NCT ID: NCT04473625
Last Updated: 2022-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
291 participants
OBSERVATIONAL
2020-07-21
2022-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stool Sample Collection Study
NCT06294873
Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
NCT02503631
Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers
NCT03563651
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT03789162
Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold
NCT03821948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast
Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Lung
Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Colorectal
Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Prostate
Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Bladder
Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Uterine
Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Kidney/Renal Pelvis
Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Ovarian
Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Liver
Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Pancreas
Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Stomach
Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Esophageal
Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stool Sample Collection
Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is willing and able to provide a stool sample.
* Subject understands the study procedures and is able to provide written informed consent to participate in the study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Exact Sciences Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
CARTI Cancer Center
Little Rock, Arkansas, United States
Marin Cancer Care
Greenbrae, California, United States
Easter Ct Hematology
Norwich, Connecticut, United States
CSNF- Central Business Office
Jacksonville, Florida, United States
Park Nicollet Institute - Oncology Research
Saint Louis Park, Minnesota, United States
St. Dominic's Gynecologic Oncology
Jackson, Mississippi, United States
Cone Health Cancer Center
Greensboro, North Carolina, United States
The Jackson Clinic
Jackson, Tennessee, United States
Community Cancer Trials of Utah
Ogden, Utah, United States
CAMC Clinical Trials Center
Charleston, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-01B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.